Over the next few years, a wave of patent expirations for leading inhaled therapies will fundamentally change the Dry Powder Inhaler (DPI) market. What used to be the domain of a small number of originator companies is rapidly becoming a crowded, global race, especially for generics. This shift will increase competition and impact how companies compete in the space.
Keeping a close eye on developments in this field is Tom Bailey, Founder and Director of 3P innovation. Tom led the technical development of (and patented) a high-speed powder filling system for the GSK Diskus inhaler, which is now used for the GSK Ellipta inhaler.
From a few originators to a crowded field of DPI players
When patents expire on leading inhaled therapies, it’s not just the drug that opens up. Over time, layers of IP around devices, filling technology and packaging also begin to fall away. That creates an opening for generic inhaler companies looking to replicate or improve on originator products and CDMOs offering platform DPI solutions. As device patents on established platforms expire, copycat and “equivalent” devices become viable. We’ll start to see more and more "me too" DPIs that closely resemble established devices. The result is clear: more companies can now credibly enter the DPI space, especially on the generic side. Competitive intensity increases not just in volume, but in diversity, different business models, different regions and different levels of technical maturity.
Patent expiry turns DPI into a timing game
Loss of exclusivity doesn’t create a gradual, long-term shift. It creates a sharp timing event. In many major markets, the first approved generic can receive a period of partial exclusivity (around 180 days). That short window can represent 40–60% of the product’s lifetime generic profit. After the first generic enters, the door quickly opens to a second wave of generics and rapid price erosion and a loss of attractive profit margins.
In this environment, the question isn’t “can we launch a DPI generic?”, the questions is “can we be first to market, capture share and stay there without being tripped up by the process and technology?”. This puts a spotlight on:
Dose accuracy.
Fast, reliable scale‑up.
Low risk of regulatory failure during validation and commercial production.
Subsequently, in this landscape, the choice of filling technology is a key decision. Traditional vacuum-based filling can introduce segregation in fine, cohesive powders. By using air to pull powder through the system, vacuum transfer may separate blends, selectively moving the fine, API particles away from the bulk. The result is compromised blend homogeneity and, ultimately, uneven dose uniformity, precisely at a time when regulators are least tolerant of variability. Any delay caused by inconsistent dosing can cost a company its first-mover position in the market, and with it a substantial share of the product’s economic value.
By contrast, well-designed mechanical filling approaches, such as our Rotary Filling Turret, are better suited to preserving blend integrity. These systems minimise the risk of segregation while still maintaining high throughput. Because the filling method itself supports blend homogeneity, development teams spend less time compensating for process-induced variability during validation and scale-up. This results is a more efficient development process and a smoother transition from formulation development to commercial manufacturing.
The rotary turret (below) lightly compresses powder into pockets on a continuously rotating disk.
Price erosion squeezes everyone except the most efficient
Once multiple generics are established, the economics shift again. The first one or two entrants can command relatively strong pricing, but as more players join, prices drop quickly. Differentiation at the product level is limited because each entrant must demonstrate equivalence. In this phase, success depends on operational excellence:
Can you manufacture at high yield with minimal waste?
Can your lines run at the required speed with complex powders?
Can you maintain regulatory compliance without expensive redesigns (and revalidations)?
For generic DPI players, the business case often depends on the cost of goods. Unlike originators, they don’t have the luxury of premium pricing to hide operational inefficiencies. Every percentage point of yield loss, every extra operator, every minute of downtime erodes already thin margins. That’s why higher‑speed lines can be so powerful, if they can run reliably with the target powders and devices. When they do, capital cost per unit drops sharply; when they don’t, waste, rework and delay quickly wipe out any advantage.
DPI differentiation shifts from 'we have the device' to 'we master the process'
As more patents fall away and more competitors enter, it becomes harder to stand out simply by having a DPI device at all. At the same time, the industry increasingly accepts that every powder behaves differently, each device involves trade‑offs, and there is no universal DPI platform that “just works” for everything. That forces players to distinguish themselves through their engineering and manufacturing capabilities. Players must now consider whether their equipment can:
Handle powders with challenging properties.
Essentially, this is through minimising segregation during filling, especially for fine, low‑dose or high‑potency powders by using mechanical dosing concepts that maintain blend homogeneity across long runs.
Achieve tight dose uniformity under real‑world conditions.
Scale from development rigs to full commercial lines without reinvention.
As more DPI players enter the market, some will lean on x‑ray and other inspection technologies as a safety blanket, a visible reassurance to internal stakeholders that “we’re checking everything”. The most competitive players will take a different route: they’ll prove they don’t need that safety blanket because their process is inherently repeatable and predictable. In a world of thin margins, the distinction between “we check every dose because we don’t trust our process” and “we don’t need to, because the process is in control” is more than philosophical – it’s the difference between a sustainable business and a short‑lived generic.
Book a conversation with Tom today to see how you can build a process you trust and a DPI business that lasts.
REFERENCES